September 15, 2023

Ab­cam’s founder Jonathan Mil­ner plans to vote against Dana­her’s $5.7 bil­lion ac­qui­si­tion of the com­pa­ny, he an­nounced Thurs­day. Mil­ner owns 6.14% of Ab­cam. He found­ed

MAPS Pub­lic Ben­e­fit Cor­po­ra­tion is tout­ing an­oth­er set of promis­ing Phase III re­sults in­ves­ti­gat­ing its MD­MA-as­sist­ed ther­a­py for post-trau­mat­ic stress dis­or­der (PTSD), with the tri­al

Bris­tol My­ers Squibb dis­closed Thurs­day at its R&D Day that it cut six pro­grams, in­clud­ing mid-stage drug can­di­dates for NASH and sol­id tu­mors. The New

Wel­come to our new look for man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls, and more. This week, we take

In the past few weeks, Lon­za has an­nounced sev­er­al new fa­cil­i­ty builds, from its part­ner­ship with Ver­tex Phar­ma­ceu­ti­cals on a new cell and gene ther­a­py

Ab­b­Vie is walk­ing away from an ex­clu­sive op­tion for Har­poon’s BC­MA-tar­get­ing T cell en­gager for mul­ti­ple myelo­ma, leav­ing the Cal­i­for­nia com­pa­ny to ad­vance the as­set

Mod­er­na is beef­ing up its pipeline over the next five years with a plan launch up to 15 new prod­ucts and ad­vance up to 50

MILAN — Benralizumab (Fasenra) allowed patients with severe eosinophilic asthma to reduce inhaled corticosteroid (ISC) use without compromising control, the SHAMAL phase IV randomized trial

Longer storage of red blood cell (RBC) units was associated with longer transplant survival in kidney transplant patients receiving early transfusions, a retrospective study in